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S360 Poster Session II(43.26 13 nmol/mg proteins) declined by 33% (p5 0.05) relative
to Syn group (686 16 nmol/mg proteins), indicating impaired GSH
synthesis. Additionally, a significant twofold (p5 0.0007) rise in he-
patic homocysteine and ophthalmic acid levels were detected in Allo
mice, linking both SAA and redox metabolic imbalance to GVHD.
To investigate mechanism(s) of GSH redox loss in GVHD, he-
patic mRNA and protein levels of gamma-glutamylcysteine ligase
[GCLC (rate-limiting enzyme)], were quantified. The hepatic
GCLC transcript and protein declined in Allo compared to Syn
mice [GCLC fold change: day +4 5 0.4 vs 1.0360.15; day +10 5
0.36 0.05 vs 1.06 0.05 (p 5 0.0004), respectively]. Target organs
like lungs and gut also revealed depletion of intracellular thiol in
Allo mice that directly correlated with the degree of T cell infiltra-
tion. Together, these data show that the GSH synthetic pathway is
specifically affected in GVHD. The tight transcriptional deregula-
tion of GCLC with depletion of GSH reserve is an early event and
precedes histopathological changes of GVHD. Identification of
modifiers of GCLC/GSH/GSSG system may provide a novel target
for treatment of GVHD.422
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Background: Graft-versus-host disease (GVHD) is one of the
primary contributing factors to morbidity and mortality following
allogeneic stem cell transplantation. Methotrexate (MTX) has
been an integral component of prophylaxis regimens against
acute GVHD when combined with calcineurin inhibitors. Recent
data suggests that lower doses of MTX are effective in prevent-
ing aGVHD and may be associated with less toxicity. However,
few comparative studies have been performed between so called
mini-MTX and standard MTX dosing schemas. The primary ob-
jective of this analysis was to compare the incidence of acute
GVHD with standard versus mini-dose MTX prophylaxis. Sec-
ondary objectives evaluated the safety and the toxicity associated
with MTX administration.
Methods: This retrospective review included allogeneic stem cell
transplant recipients at Memorial Sloan-Kettering Cancer Center
(MSKCC) between 8/1/2003-8/16/2010 that received standard or
mini-MTX as part of post-transplant GVHD prophylaxis. Standard
MTX dosing was defined as 15 mg/m2 on day 1 with subsequent
doses of 10 mg/m2 administered on days 3, 6 and 11. The mini-
MTX group included patients who never received a dose of 15
mg/m2.
Results: 226 patients (138 standard and 88 mini-MTX) were in-
cluded in the analysis. Based on clinical practice at MSKCC,
the standard dose arm had a higher frequency of leukemia patients
while the mini-dose group had a higher frequency of lymphoma
patients. Median age at transplant was 27 years and 50 years for
standard and mini-dose groups, respectively (p\0.001). The me-
dian follow up for patients alive without acute GVHD was 33
months (range 10-90 months). Cumulative incidence of GVHD
at 3 months was 28.9% [95% CI: (21.4-36.6%)] and 28.4%
[95% CI (19.0-37.9%)] for the standard and mini-dose treatment
arms (p 5 0.91). The adult subgroup also revealed no difference
in aGVHD at 3 months (p 5 0.56). A univariate analysis showed
that CMV seropositivity was positively associated with higher
rates of GVHD (HR: 1.81 [95% CI: 1.14-2.85, p 5 0.01). Dose
adjustments or delay of MTX were significantly different between
groups (43.5% in standard arm vs. 15.9% mini-dose arm,
p\0.0001) suggesting an improved toxicity profile, however this
may have been impacted by the primary conditioning regimen.
Conclusion: Prophylaxis with mini-MTX may be associated with
a similar incidence of aGVHD and an improved toxicity profile
when compared to a standard dose schema.423
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Strategies to suppress GVHD are often associated with broader
suppression of the immune system leading to a compromised
GVT effect. We have demonstrated that genetically engineered T
cells over-expressing TNF-Related Apoptosis Inducing Ligand
(TRAIL) have enhanced GVT effects and explicitly suppress
GVHD. TRAIL induces apoptotic signals through death receptor
(DR) 4 and 5 molecules (only DR5 in mice) expressed on certain tu-
mors and inducible on others. TRAIL is therefore an attractive can-
didate for genetic engineering of donor T cells to enhance their
GVT potential.
Mature T cells derived from donor B6 splenocytes were trans-
duced with a lentiviral TRAIL expression vector. The transduced
TRAIL+ T cells were adoptively transferred into lethally irradiated
CBF1 recipients of T cell depleted allografts and LB27.4 tumor to
assess their GVHD and GVT activity. TRAIL+ T cells displayed
significantly enhanced antitumor immunity compared to mock
(GFP)-transduced controls in vitro and upon transfer into tumor
bearing allo-BMT recipients (p\0.01, 100% survival in TRAIL+
T cell group). Additionally, the recipients treated with TRAIL+ T
cells had significantly less GVHD lethality and morbidity. This
was observed across multiple GVHD models (B6 / CBF1 and
B10.BR/ B6). Using in vitro proliferation assays and in vivo biolu-
minescent imaging, we found that TRAIL+ T cells suppressed pro-
liferation of non-transduced alloreactive T cells. To explore the
factors contributing to TRAIL-mediated suppression of GVHD,
we used recipients deficient in DR5 (DR5ko) and found that
TRAIL+ T cells suppress GVHD by impairing host APC functions.
Precursor (pre)T cells can regenerate the T cell compartment with-
out GVHD. We generated and expanded TRAIL+ preT cells using
the OP9-DL1 co-culture system. Adoptive transfer of B6 TRAIL+
preT cells into syngeneic-transplanted BALB/c mice reconstituted
the T cell compartment with TRAIL+ T cells and caused enhanced
antitumor activity (p\0.05) compared to controls.
Collectively, our data demonstrate that donor T cells genetically
engineered to expressTRAIL can enhanceGVTeffects and suppress
lethal GVHD through impairment of host APCs in recipients of
allo-HSCT. Furthermore, we demonstrated that allogeneic ex vivo
generated preT cells expressing TRAIL could mediate a strong pro-
tection against tumor challenge in syngeneic HSCT recipients, rep-
resenting an ‘‘off the shelf’’ strategy in both allogeneic and
autologous recipients.424
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Introduction: Chronic graft versus host disease (GVHD) of lung is
associated with higher transplant related morbidity and mortality af-
ter allogeneic hematopoeitic cell transplant (HCT). Risk factors for
lung GVHD are not yet fully elucidated in detail. We attempted to
identify clinical risk factors for lung GVHD after allogeneic HCT
based on single center experience.
Methods: 401 patients were transplanted between year 2000 and
2007 at the Princess Margaret Hospital, Toronto, Canada. 280
(70%) and 121 (30%) patients received peripheral blood stem cell
(PBSC) and bonemarrow (BM) as a source of stem cells, respectively.
Monitoring with pulmonary function tests (PFT) were performed
prior to transplant, at day 180, then annually. PFT was also
